{"name":"Darier","slug":"darier","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Minocycline vs Lymecycline","genericName":"Minocycline vs Lymecycline","slug":"minocycline-vs-lymecycline","indication":"Acne vulgaris","status":"marketed"}]}],"pipeline":[{"name":"Minocycline vs Lymecycline","genericName":"Minocycline vs Lymecycline","slug":"minocycline-vs-lymecycline","phase":"marketed","mechanism":"Both minocycline and lymecycline are tetracycline antibiotics that inhibit bacterial protein synthesis by binding to the 30S ribosomal subunit.","indications":["Acne vulgaris","Rosacea","Bacterial infections (skin and soft tissue)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxQekdVYUlCaVN3VWNUc3VLWkRfdWdIRGd5cGhYcEdDYnlGV0ZqRVZrTHd6VXo3T1FRSTlOSmlTbFV0aUNEZnRSNzQ0elhKN3Z2eTZjVENPcFhxNnloa0JCTDYzbDZTU0thWTRtUG1yNHdPMG1WR1pfdjdvdVFnYkUwWWVzWWp4dw?oc=5","date":"2024-08-22","type":"trial","source":"pharmaphorum","summary":"Rare disease drug from LEO's Timber felled by failed study - pharmaphorum","headline":"Rare disease drug from LEO's Timber felled by failed study","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE1IOU5MX2Q1VlZ4NXJINWFNemNLYnZWZGNOWm5hYVFxZ3ctZzB6WlhqV19BSjM4MjNsb05iWHFpV3E1cXhzTGxYSVpFbHRJdw?oc=5","date":"2020-09-12","type":"pipeline","source":"Stock Titan","summary":"Latest SLGL News - Sol-Gel Technologies Ltd. Announces Pricing... - Stock Titan","headline":"Latest SLGL News - Sol-Gel Technologies Ltd. Announces Pricing...","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQd003MVNYQlBOVzlxTXM4VlZCRjFPX3YtZE5DNkJWNDVGb3VIQXg3MW5CUFhKNHFjZEM2b3dvZkJFVmtlYzNfTWRPVldzMmhLR2tNaVR4QlpxOWVSSU4zVlhHVjBDNi16YThOY0ZHSzE0RnpvT0RBZ3FDY3dGeDFkd2FXTDZua21senRRc291eWdURWZy?oc=5","date":"2017-09-13","type":"pipeline","source":"Fierce Biotech","summary":"BridgeBio Pharma gains $135M for genetic disease work - Fierce Biotech","headline":"BridgeBio Pharma gains $135M for genetic disease work","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}